Mumbai, Dec. 10 -- Denosumab is a monoclonal antibody with several indications related to bone health, primarily used in the treatment of osteoporosis and in preventing skeletal complications in cancer patients. The launch of Zyrifa will help treat patients with bone metastases resulting from breast, prostate, lung, myeloma, kidney, thyroid, head and neck, and other solid tumours. Bone metastasis occurs when cancer spreads to the bones or other organs, indicating an advanced stage of disease. Zyrifa is priced at an MRP of Rs 12,495.

Bone metastases are a serious complication across multiple cancers, significantly affecting patient quality of life. Patients may experience pain, fractures, spinal cord compression, reduced mobility and loss...